Centauri Minerals Inc., a mineral exploration company focused on Northern Argentina, has upgraded its trading to the OTCQX Best Market from the Pink Limited Market, starting October 26, 2026. This move enhances transparency and accessibility for U.S. investors, allowing them to access real-time quotes and financial disclosures more easily. Centauri holds significant gold, copper, and silver resources at its Rio Grande project and aims to increase visibility as it begins drilling operations. The upgrade reflects the company's commitment to high financial standards and corporate governance, aligning with OTCQX requirements.
Centauri Minerals Inc.'s recent trading upgrade to the OTCQX Best Market coincides with a broadly positive day for the Basic Materials sector on Pluang, where 54 of 83 priced US stocks rose. Notable movers include Harmony Gold Mining Co. (HMY) at USD 16.32 with a +3.10% change and a typical hold time of 45 days on Pluang, Aya Gold & Silver Inc. (AYA) at USD 23.07 down -2.94%, and Sherwin-Williams Company (SHW) at USD 346.74 up +2.87%, as of Oct 26, 2026 17:11 WIB.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
